Introduction: Melperone, a butyrophenone neuroleptic, is frequently used for its sleep-inducing properties. Despite its common use for more than 30 years, it is not yet characterized regarding its effects on cytochrome P450 s (CYPs). In an open pilot study, effects of melperone on the steady-state blood levels of venlafaxine, a recently introduced serotonin- and noradrenaline reuptake inhibiting antidepressant, were assessed.
Methods: The dose-corrected serum concentrations of venlafaxine and O-desmethylvenlafaxine were analyzed retrospectively in a therapeutic drug-monitoring (TDM) database comprising 94 patients. In addition, three patients received venlafaxine and melperone concomitantly and the serum concentrations of venlafaxine and O-desmethylvenlafaxine were analyzed before, during, and after melperone co-medication. The effect of melperone on CYP2D6 was further assessed in seven patients by means of the dextromethorphan O-demethylation, which serves as a CYP2D6 probe reaction.
Results: Patients treated concomitantly with venlafaxine and melperone had significantly higher (mean ± SD) venlafaxine (3.27 ± 2.9 vs. 0.97 ± 0.99 ng/ml per mg/d; p < 0.05) and lower O-desmethylvenlafaxine serum concentrations (0.69 ± 0.35 vs. 1.51 ± 0.9 ng/ml per mg/d; p < 0.01) compared to patients without melperone comedication. In the three patients, venlafaxine serum concentrations increased, on average by 52 % during melperone co-medication, whereas O-desmethylvenlafaxine was decreased, on average by 29 %. Administration of melperone over three days elevated the ratio of dextromethorphan to dextrorphan from 0.044 ± 0.04 to 0.09 ± 0.083 (p < 0.05).
Discussion: This study pointed to an inhibitory effect of melperone on the O-demethylation of venlafaxine. Because the O-demethylation of venlafaxine is almost exclusively catalyzed by CYP2D6 it is concluded that melperone is an inhibitor of CYP2D6. The hypothesis was further corroborated by the inhibitory effect of melperone on the dextromethorphan O-demethylation.
References
-
1 Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie. Berlin, Heidelberg, New York; Springer 2001
-
2
Bjerkenstedt L.
Melperone in the treatment of schizophrenia.
Acta Psychiatr Scand Suppl.
1989;
352
35-39
-
3
Bjerkenstedt L, Harnyrd C, Grimm V, Gullberg B, Sedvall G.
A double blind comparison of melperone and thiothixene in psychotic women using a new rating scale, the CPRS.
Arch Psychiatr Nervenkr.
1978;
14
157-172
-
4
Borbely A A.
The S-deficiency hypothesis of depression and the two-process model of sleep regulation.
Pharmacopsychiat.
1987;
20
23-29
-
5
Borgstrom L, Larsson H, Molander L.
Pharmacokinetics of parenteral and oral melperone in man.
Eur J Clin Pharmacol.
1982;
23
173-176
-
6
Christensen I, Geismar L, Kirkegaard A, Kirkegaard G.
Additional studies on side effects of melperone in long-term therapy for 1 - 20 years in psychiatric patients.
Arzneimittelforschung.
1986;
36
855-860
-
7
Christensson E G.
Pharmacological data of the atypical neuroleptic compound melperone (Buronil).
Acta Psychiatr Scand Suppl.
1989;
352
7-15
-
8
Eap C B, Bertel-Laubscher R, Zullino D, Amey M, Baumann P.
Marked increase of venlafaxine enatiomer concentration as a consequence of metabolic interaction: A case report.
Pharmacopsychiat.
2000;
33
112-25
-
9
Fogelman S M, Schmider J, Venkatakrishnan K, von Moltke L L, Harmatz J S, Shader R I, Greenblatt D J.
O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants.
Neuropharmacology.
1999;
20
480-490
-
10
Ford D E, Cooper-Patrick L.
Sleep disturbances and mood disorders: an epidemiologic perspective.
Depress Anxiety.
2001;
14
3-6
-
11
Halpert J R.
Structural basis of selective cytochrome P450 inhibition.
Annu Rev Pharmacol Toxicol.
1995;
35
29-53
-
12
Härtter S, Baier D, Dingemanse J, Ziegler G, Hiemke C.
Automated determination of dextromethorphan and its main metabolites in human plasma by high performance-liquid chromatography and column switching.
Ther Drug Monit.
1996;
18
297-303
-
13
Holliday S M, Benfield P.
Venlafaxine: A review of its pharmacology and therapeutic potential in depression.
Drugs.
1995;
49
280-294
-
14
Köhler D, Härtter S, Fuchs K, Sieghart W, Hiemke C.
CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication.
Pharmacogenetics.
1997;
7
453-61
-
15
Kretzschmar R, Otto J, Teschendorf H J, Worstmann W.
Pharmacological investigation of 4’-fluoro-4-(4-methyl-peperodono)-butyrophenone with respect to its sedative and sleep-inducing properties.
Arzneimittelforschung.
1976;
26
1073-1076
-
16
Küpfer A, Schmid B, Pfaff G.
Pharmacogenetics of dextromethorphan O-demethylation in man.
Xenobiotica.
1986;
16
421-33
-
17
Lessard E, Yessine M -A, Hamelin B A, O’Hara G, LeBlanc J, Turgeon J.
Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
Pharmacogenetics.
1999;
9
435-443
-
18
Molander L, Borgström L.
Relationship between plasma concentration and arousal in normal subjects after single oral and parenteral doses of melperone, a butyrophenone neuroleptic.
Psychopharmacology.
1983;
79
111-114
-
19
Otton S V, Ball S E, Cheung S W, Inaba T, Rudolph R L, Sellers E M.
Venlafaxine oxidation in vitro is catalysed by CYP2D6.
Br J Clin Pharmacol.
1996;
41
149-156
-
20
Richelson E, Souder T.
Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds.
Life Sci.
2000;
68
29-39
-
21
Salin-Pascual R J, Galicia-Polo L, Drucker-Colin R.
Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers.
J Clin Psychiatry.
1997;
58
348-350
-
22
Settle EC j r.
Antidepressant drugs: disturbing and potentially dangerous adverse effects.
J Clin Psychiat..
1998;
59 Suppl 16
25-30
-
23
Smith D A, Jones B C.
Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes.
Biochem Pharmacol.
1992;
44
2089-2098
-
24
Syvälahti A KG, Lindberg R, Kallio J, De Vocht M.
Inhibitory effects of neuroleptics on debrisoquine oxidation in man.
Br J Clin Pharmacol.
1986;
22
89-92
-
25
Vefkind A H, Haffmans P MJ, Hoencamp E.
Venlafaxine serum levels and CYP2D6 genotype.
Ther Drug Monit.
2000;
22
202-208
-
26
Weigmann H, Härtter S, Maehrlein S, Kiefer W, Krämer G, Dannhardt G, Hiemke C.
Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column switching high performance liquid chromatography.
J chromatogr B.
2001;
759
63-71
Sebastian Härtter, Ph. D.
Neurochemical Lab., Department of Psychiatry
University of Mainz
Untere Zahlbacherstraße 8
55131-Mainz
Germany
Phone: +49-6131-176788
Fax: +49-6131-176789
Email: sepp@psychiatrie.klinik.uni-mainz.de
